DDInter1631 DDInter1742
Safinamide is for the treatment of parkinson's disease. It was approved in Europe in February 2015, and in the United States on March 21, 2017.
Talazoparib is an inhibitor of mammalian polyadenosine 5’-diphosphoribose polymerases (PARPs), enzymes responsible for regulating essential cellular functions, such as DNA transcription and DNA repair. Developed by Pfizer, talazoparib was first approved by the FDA in October 2018 and by the EMA in June 2019. It was approved by Health Canada in September 2020. Talazoparib is currently used in the treatment of BRCA-mutated breast cancer and HRR-mutated prostate cancer.[L47236, L47301, L47306]
Talazoparib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Simeprevir
Talazoparib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Human adenovirus e serotype 4 strain cl-68578 antigen
Talazoparib {u} may lead to a major life threatening interaction when taken with {v} Measles virus vaccine live attenuated
Talazoparib {u} may lead to a major life threatening interaction when taken with {v} Smallpox (Vaccinia) Vaccine, Live
Talazoparib may cause a moderate interaction that could exacerbate diseases when taken with Simeprevir
Talazoparib may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen
Talazoparib may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated
Talazoparib may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live